Chrysalis Capital invests in pioneering innovations that extend human lifespans. The market for increasing life expectancy by one year stands at $38 trillion today and will be worth $367 trillion in a decade. As global populations age, we create a future where living 150 healthy years becomes possible through advanced genomics, regenerative medicine, and beyond.
We collaborate with cutting-edge innovators to transform life extension. Through strategic investments targeting
the most critical challenges in biotechnology and regenerative medicine, Chrysalis Capital plays a central role in the growth of this rapidly expanding market.
